Changes in Hong Kong stocks | Hengrui Pharmaceutical (01276) rose more than 5% in the afternoon CLDN 18.2 ADC gastric cancer indications included in the list of breakthrough treatment varieties

The Zhitong Finance App learned that Hengrui Pharmaceutical (01276) rose more than 5% in the afternoon. As of press release, it had risen 5.19% to HK$74.95, with a turnover of HK$556.8871 million.

According to the news, Hengrui Pharmaceutical announced that its self-developed antibody drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), injectable SHR-A1904, has been officially included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration. This drug is intended to treat CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that has received at least previous first-line system treatment.

According to the announcement, this inclusion in the breakthrough treatment procedure is based on the potential clinical value of the drug in specific indications. The Drug Evaluation Center will prioritize review resources for this drug and strengthen research and development guidance to accelerate its clinical development and marketing process. Gastric cancer is a high-incidence malignant tumor in China. In 2020, the number of new cases and deaths in China accounted for about 44% and 48.6% of the world, respectively, and there is a huge unmet clinical need. The CLDN 18.2 target is highly expressed in various gastrointestinal tumors. It is currently one of the popular targets for tumor drug development. No similar ADC product has been approved for marketing worldwide.